Related references
Note: Only part of the references are listed.Apoptosis Signal- Regulating Kinase 1 Is a Novel Target Molecule for Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion
Kensuke Toyama et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2014)
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis
A. Liakos et al.
DIABETES OBESITY & METABOLISM (2014)
SGLT2 inhibitors in the treatment of type 2 diabetes
Farhad M. Hasan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Rosuvastatin Ameliorates Early Brain Injury after Subarachnoid Hemorrhage via Suppression of Superoxide Formation and Nuclear Factor-Kappa B Activation in Rats
Ken Uekawa et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2014)
Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors
Raymond V. Oliva et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2014)
Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
Naoto Terami et al.
PLOS ONE (2014)
Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions
Geert Jan Biessels et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
Anthony H. Barnett et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension
Florian Gembardt et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
Volker Vallon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Effect of Strict Glycemic Control in Patients With Diabetes Mellitus on Frequency of Macrovascular Events
Amita Singh et al.
AMERICAN JOURNAL OF CARDIOLOGY (2013)
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice
T. Nagata et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control
Martin Ridderstrale et al.
CARDIOVASCULAR DIABETOLOGY (2013)
The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study
Arne Ring et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice
Juan Jose Ramos-Rodriguez et al.
PSYCHONEUROENDOCRINOLOGY (2013)
Effects of a New SGLT2 Inhibitor, Luseogliflozin, on Diabetic Nephropathy in T2DN Rats
Naoki Kojima et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
Scott C. Thomson et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2012)
Effects of SGLT2 inhibitors on cardiovascular outcomes
Celine Foote et al.
DIABETES & VASCULAR DISEASE RESEARCH (2012)
Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats
L. Thomas et al.
DIABETES OBESITY & METABOLISM (2012)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
R. Grempler et al.
DIABETES OBESITY & METABOLISM (2012)
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ele Ferrannini et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats
Horacio Osorio et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2012)
Decreased Cerebrovascular Brain-Derived Neurotrophic Factor-Mediated Neuroprotection in the Diabetic Brain
Deepti Navaratna et al.
DIABETES (2011)
Attenuation of Brain Damage and Cognitive Impairment by Direct Renin Inhibition in Mice With Chronic Cerebral Hypoperfusion
Yi-Fei Dong et al.
HYPERTENSION (2011)
Cognitive and Emotional Alterations Are Related to Hippocampal Inflammation in a Mouse Model of Metabolic Syndrome
Anne-Laure Dinel et al.
PLOS ONE (2011)
Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes
Y. F. Dong et al.
DIABETOLOGIA (2010)
Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice
Masaya Fukuda et al.
JOURNAL OF HYPERTENSION (2010)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
N. Sarwar et al.
LANCET (2010)
Insulin metabolism and the risk of Alzheimer disease The Rotterdam Study
E. M. C. Schrijvers et al.
NEUROLOGY (2010)
Insulin resistance is associated with the pathology of Alzheimer disease The Hisayama Study
T. Matsuzaki et al.
NEUROLOGY (2010)
Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons
Alexis M. Stranahan et al.
NATURE NEUROSCIENCE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Increasing cardiovascular disease burden due to diabetes mellitus - The Framingham Heart Study
Caroline S. Fox et al.
CIRCULATION (2007)
Role of oxidative stress in cardiac hypertrophy and remodeling
Eiki Takimoto et al.
HYPERTENSION (2007)
Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis
Eiichiro Yamamoto et al.
JOURNAL OF HYPERTENSION (2006)
Attenuation of renal injury in db/db mice overexpressing superoxide dismutase -: Evidence for reduced superoxide-nitric oxide interaction
FR DeRubertis et al.
DIABETES (2004)
Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents
XL Li et al.
NEUROSCIENCE (2002)
Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na+-glucose cotransporter inhibitor T-1095
K Arakawa et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Share Paper
